Therefore, suboptimal GLP-1 secretion, in the context of resistance to GLP-1, is also involved in the pathogenesis of “diabesity”, and GLP-1 receptor agonists are fundamental options for the treatment of T2D and MASD [34,35]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.